- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01690312
Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy
Clinical Study to Assess the Acute and Chronic Effects of a High-DHA Fish Oil on Fasting and Post-Prandial Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
This study involves fasted and post-prandial components.
Fasted Study:
Participants will provide fasting blood samples pre-and post-intervention [4-week administration of supplement or placebo] in Treatment Period I. Participants will again provide fasting blood samples pre-and post-intervention [4-week administration of supplement or placebo, opposite to Treatment Period I] during Treatment Period II.
There will be a 4-week washout period during the two Treatment Periods.
Post-prandial study:
Participants will also complete a post-prandial study pre-and post-intervention during each Treatment Period.
Typ studie
Zápis (Očekávaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Ontario
-
Guelph, Ontario, Kanada, N1G 0B4
- Nutrasource Diagnostics Inc.
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Be an adult between the ages of 18 and 70;
- Be a male or a post-menopausal female who has gone a minimum of one year since their last menses;
- Be taking Statin medication at a stable dose for a minimum of four weeks prior to study commencement [and whom have reached a target LDL level];
- Have elevated fasting triglyceride levels [greater than 1.5 mmol/L but less than 5.7 mmol/L];
- Have fasting blood glucose levels below the study cut-off [less than 7.0 mmol/L];
- Have a Body Mass Index (BMI) less than 35.0
- Be taking natural health products BUT agree to cease consumption during the study period and a 4-week pre-study washout prior to study commencement. Study participants will be allowed to consume a daily multivitamin if they have been doing so at a stable dose for a minimum of three months prior to study commencement.
Exclusion Criteria:
- Be younger than 18 years of age or older than 70 years of age;
- Be an adult pre- or peri-menopausal female;
- Not have taken Statin medication at a stable dose for a minimum of 4 weeks prior to study commencement;
- Have fasting triglyceride levels outside of study limits[ie/ less than 1.5 mmol/L or greater than 5.7 mmol/L];
- Have elevated fasting blood glucose levels [greater or equal to 7.0 mmol/L];
- Have high blood pressure [greater than 140/100]
- Have a Body Mass Index (BMI) equal to or greater than 35.0
- Have a pre-existing cardiovascular disease or illness, including angina, myocardial infarction, stroke, intermittent claudication or transient ischemic attack;
- Have a known allergy to fish and/or fish oil, olive oil, soy or Vitamin E;
- Be taking natural health products but are unwilling to cease consumption during the study period and a 4-week pre-study washout prior to study commencement;
- Consume more than two (2) fish meals on a weekly basis
- Consume excessive amounts of alcohol on a weekly basis [more than 10 alcoholic drinks per week];
- Anticipate or have planned surgery during the course of the study.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Crossover Assignment
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: 1 (Dietary Supplement - Fish Oil)
On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed. On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol. |
On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day.
Each capsule contains 1000 mg of fish oil [620 mg of DHA and 150 mg of EPA], providing a total daily dosage of 4000 mg of fish oil [3080 mg of DHA+EPA].
|
|
Experimentální: 2 (Placebo)
On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed. On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol. |
On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day.
Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Triglyceride [TG]
Časové okno: 0 and 4 weeks
|
Fasted and postprandial samples will be drawn (hourly up to 6 hours).
|
0 and 4 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Glucose
Časové okno: 0 and 4 weeks
|
Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).
|
0 and 4 weeks
|
|
Insulin
Časové okno: 0 and 4 weeks
|
Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).
|
0 and 4 weeks
|
|
Total cholesterol [TC]
Časové okno: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
High-density lipoprotein [HDL]
Časové okno: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Low-density lipoprotein [LDL]
Časové okno: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Very low-density lipoprotein [VLDL]
Časové okno: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Lipoprotein A
Časové okno: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Intermediate-density lipoprotein [IDL]
Časové okno: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Remnant Lipoproteins
Časové okno: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
High-sensitivity C-Reactive Protein [hs-CRP]
Časové okno: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Homocysteine
Časové okno: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Essential Fatty Acid Profile
Časové okno: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Apolipoprotein B
Časové okno: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Apolipoprotein A-1
Časové okno: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Alison Duncan, Ph.D., R.D., University of Guelph
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
- Inzulín
- Lidé
- Kardiovaskulární onemocnění
- DHA
- Rybí tuk
- Statiny
- Glukóza
- Triglyceridy
- Post-prandiální
- Homocystein
- EPA
- Lipoproteiny
- Postil se
- Apolipoprotein B
- High-DHA
- Total cholesterol [TC]
- High-density lipoprotein [HDL2, HDL3]
- Low-density lipoprotein [LDL1+2+3+4]
- Lipoprotein A [Lp(a)]
- Intermediate-density lipoprotein (IDL)
- Very low-density lipoprotein (VLDL1+2, VLDL3)
- Remnant Lipoproteins
- High-sensitivity C-Reactive Protein [hs-CRP]
- Essential Fatty Acid Profile
- Apolipoprotein A-1
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 11-09-002
- 150038 (Health Canada)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Fish Oil
-
Hospital Infantil de Mexico Federico GomezCentro Universitario del Sur, Guadalajara; Instituto de Servicios Descentralizados...DokončenoRezistence na inzulín | Dětská obezita | Metabolické komplikaceMexiko
-
Assiut UniversitySouth Egypt Cancer InstituteDokončenoAkutní myeloidní leukémieEgypt
-
Morris Innovative IncorporatedDeborah Heart and Lung CenterNeznámýCévní onemocněníSpojené státy
-
Gadjah Mada UniversityNational Institute of Health Research and Development, Ministry of Health...DokončenoSouvisející s těhotenstvímIndonésie
-
Kerecis Ltd.Zápis na pozvánkuChirurgická rána | Diabetický vřed na nohou | Žilní bércový vřed | Dekubity | Rány | Vyztužení měkkých tkáníSpojené státy
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNábor
-
Sarah KeimCures Within Reach; Marci and Bill Ingram Fund for Autism Spectrum Disorders...DokončenoPředčasný porod | Chování dítěte | Vývoj dítěteSpojené státy
-
Société des Produits Nestlé (SPN)DokončenoZdraví dobrovolníciŠvýcarsko
-
CalanusBiofortis Clinical Research, Inc.Dokončeno